399 related articles for article (PubMed ID: 30057690)
1. HER3 signaling and targeted therapy in cancer.
Mishra R; Patel H; Alanazi S; Yuan L; Garrett JT
Oncol Rev; 2018 Jan; 12(1):355. PubMed ID: 30057690
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
3. Targeting of erbB3 receptor to overcome resistance in cancer treatment.
Ma J; Lyu H; Huang J; Liu B
Mol Cancer; 2014 May; 13():105. PubMed ID: 24886126
[TBL] [Abstract][Full Text] [Related]
4. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
5. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
6. HER3/ErbB3, an emerging cancer therapeutic target.
Zhang N; Chang Y; Rios A; An Z
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):39-48. PubMed ID: 26496898
[TBL] [Abstract][Full Text] [Related]
7. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathways: HER3 targeted therapy.
Gala K; Chandarlapaty S
Clin Cancer Res; 2014 Mar; 20(6):1410-6. PubMed ID: 24520092
[TBL] [Abstract][Full Text] [Related]
9. siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells.
Yuan HH; Yang YN; Zhou JH; Li YJ; Wang LY; Qin JW; Liu T; Li ZZ; Zhou QX; Wei XL; Zhang TT; Huang P; Zhang WJ; Liu L; Du XX; Han Y
Oncotarget; 2017 Aug; 8(32):52584-52593. PubMed ID: 28881753
[TBL] [Abstract][Full Text] [Related]
10. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
[TBL] [Abstract][Full Text] [Related]
11. Understanding the biology of HER3 receptor as a therapeutic target in human cancer.
Lyu H; Han A; Polsdofer E; Liu S; Liu B
Acta Pharm Sin B; 2018 Jul; 8(4):503-510. PubMed ID: 30109175
[TBL] [Abstract][Full Text] [Related]
12. HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer.
Majumder A
Cells; 2023 Oct; 12(21):. PubMed ID: 37947595
[TBL] [Abstract][Full Text] [Related]
13. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
14. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
15. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
16. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
17. Development of Effective Therapeutics Targeting HER3 for Cancer Treatment.
Liu X; Liu S; Lyu H; Riker AI; Zhang Y; Liu B
Biol Proced Online; 2019; 21():5. PubMed ID: 30930695
[TBL] [Abstract][Full Text] [Related]
18. Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance.
Temraz S; Mukherji D; Shamseddine A
Crit Rev Oncol Hematol; 2016 May; 101():151-7. PubMed ID: 27017409
[TBL] [Abstract][Full Text] [Related]
19. Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.
Malm M; Frejd FY; Ståhl S; Löfblom J
MAbs; 2016 Oct; 8(7):1195-1209. PubMed ID: 27532938
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
